Annals of Oncology Advance Access originally published online on January 29, 2009
Annals of Oncology 2009 20(4):674-680; doi:10.1093/annonc/mdn680
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gastrointestinal tumors |
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
1 CRLC Val d'Aurelle, Montpellier
2 CRLC Eugène Marquis, Rennes, France and European University in Brittany
3 CRLC René Gauducheau, St Herblain
4 CRLC Claudius Régaud, Toulouse
5 Clinique Sainte Catherine, Avignon
6 CRLC Antoine Lacassagne, Nice
7 Institut Bergonié, Bordeaux
8 CH R. Debré, Reims
9 CRLC Paul Papin, Angers
10 Institut Gustave Roussy, Villejuif
11 CRLC Alexis Vautrin, Vandoeuvre-les-Nancy
12 CH La Timone, Marseille
13 CHU du Bocage, Dijon, France
* Correspondence to: Prof. M. Ychou, Centre de Recherche et de Lutte contre le Cancer Val d'Aurelle, 208 rue des apothicaires, 34298 Montpellier Cedex 05, France. Tel: +33-4-67-61-30-66; Fax: +33-4-67-61-30-22; E-mail: marc.ychou{at}valdorel.fnclcc.fr
Background: This multicenter adjuvant phase III trial evaluated the addition of irinotecan to LV5FU2 in colon cancer patients at high risk of relapse.
Patients and methods: A total of 400 patients with histologically proven primary colon cancer with postoperative N1 detected by occlusion/perforation or N2 were randomised to: A—LV5FU2 [leucovorin 200 mg/m2, 2-h infusion, 5-fluorouracil (5-FU) 400 mg/m2 bolus, 600 mg/m2 22-h continuous infusion, days 1 and 2] or B—LV5FU2 + IRI (irinotecan 180 mg/m2 90-min infusion day 1 + LV5FU2) fortnightly for 12 cycles. Primary end point was disease-free survival (DFS).
Results: Median follow-up was 63 months. Significantly more T4 tumours and 15 or more positive lymph nodes were observed in arm B. 5-FU relative dose intensity (RDI) was >0.80 for 94% and 77% in arms A and B, respectively (P < 0.001). Irinotecan RDI was >0.80 for 70% patients. There were more grades 3 and 4 neutropenia in arm B (4% versus 28%, P < 0.001). The 3-year DFS was 60% [95% confidence interval (CI) 53% to 66%] and 51% (95% CI 44% to 58) in arms A and B, respectively. No difference was observed [hazard ratio (HR) = 1.12, 95% CI 0.85–1.47, P = 0.42] even when adjusted for prognostic factors (adjusted HR = 0.98, 95% CI 0.74–1.31, P = 0.92). The 5-year overall survival (OS) was 67% (95% CI 59% to 73%) and 61% (95% CI 53% to 67%) in arms A and B, respectively.
Conclusion: Adjuvant LV5FU2 + IRI compared with LV5FU2 alone in patients at high risk of relapse showed no improvement in DFS and OS.
Key words: adjuvant chemotherapy, colon cancer, irinotecan
Received for publication April 14, 2008. Revision received September 22, 2008. Accepted for publication September 23, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in Ann Oncol:
- in this issue
Ann Oncol 2009 20: 603.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  E. Van Cutsem, R. Labianca, G. Bodoky, C. Barone, E. Aranda, B. Nordlinger, C. Topham, J. Tabernero, T. Andre, A. F. Sobrero, et al. Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3 J. Clin. Oncol., July 1, 2009; 27(19): 3117 - 3125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. O'Connell Oxaliplatin or Irinotecan As Adjuvant Therapy for Colon Cancer: The Results Are In J. Clin. Oncol., July 1, 2009; 27(19): 3082 - 3084. [Full Text] [PDF]
|
|